(Q38152774)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Markus Cornberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

K Port

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

B Calle Serrano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

A A Markova

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

L Sollik

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

M P Manns

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

H Wedemeyer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

16 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

11-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1365-1372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

27 February 2020

cites work

1 reference

Natural history of acute and chronic hepatitis C.

21 January 2018

1 reference

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

21 January 2018

1 reference

Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?

21 January 2018

1 reference

Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

21 January 2018

1 reference

Optimal treatment with boceprevir for chronic HCV infection.

21 January 2018

1 reference

Optimal treatment with telaprevir for chronic HCV infection

21 January 2018

1 reference

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

21 January 2018

1 reference

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

21 January 2018

1 reference

Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients

21 January 2018

1 reference

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

21 January 2018

1 reference

Endocrine manifestations of hepatitis C virus infection.

21 January 2018

1 reference

Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach

21 January 2018

1 reference

Insulin resistance and hepatitis C: an evolving story

21 January 2018

1 reference

Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity

21 January 2018

1 reference

Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients

21 January 2018

1 reference

Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

21 January 2018

1 reference

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data

21 January 2018

1 reference

Novel therapies for hepatitis C - one pill fits all?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12523

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127648%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference